Form 4: Aileron Therapeutics President and COO Reports Conversion of Preferred Stock and Disposed of Common Stock

James Brian Windsor, President and COO of Aileron Therapeutics, reports the conversion of Series X Preferred Stock into common stock and the disposal of 2,000 common stock shares on March 5, 2024.

Summary

• On March 5, 2024, James Brian Windsor, the President and COO of Aileron Therapeutics, filed a Form 4.
• The filing reports the automatic conversion of Series X Non-Voting Convertible Preferred Stock into common stock.
• Each share of Series X Preferred Stock converted into 1,000 shares of common stock, resulting in the acquisition of 2,000 shares.
• Windsor also disposed of 2,000 shares of common stock.
• Following the reported transactions, Windsor directly owns 7,122 shares of common stock.
• Windsor also indirectly owns 225 shares of common stock through his son, but disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions and stock conversions, which are common in publicly traded companies.

Stakeholder Impact

• The conversion of preferred stock to common stock may slightly dilute existing shareholders' equity.

Key Dates